Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells

Clinical and Experimental Allergy

Volumn 34, Issue 9, 2004, Pages 1373-1378

  Wilcock, L K ^a   Francis, J N ^a   Durham, S R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Adjuvants; Allergy; Aluminium hydroxide; Human; Immunotherapy; T lymphocytes

Indexed keywords

ALUMINUM HYDROXIDE; B7 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 5;

ALLERGY; ARTICLE; ATOPY; CELL PROLIFERATION; CELL STIMULATION; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHINITIS; T LYMPHOCYTE; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALLERGENS; ALUMINUM HYDROXIDE; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CELLS, CULTURED; DOWN-REGULATION; FEMALE; HLA ANTIGENS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-5; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE GLYCOPROTEINS; PHLEUM; POLLEN; RHINITIS, ALLERGIC, SEASONAL; TH2 CELLS;

EID: 4544370248     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.02052.x     Document Type: Article

References (31)

1. Clements CJ, Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 2002; 20 (Suppl. 3):S24-33.
2. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998; 32:155-72.
3. Volk VK, Bunney WE. Diphtheria immunization with fluid toxoid and aluminium precipitated toxoid. Am J Public Health 1942; 32:690-9.
4. Mark A, Bjorksten B, Granstrom M. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine 1995; 13:669-73.
5. Bentley AM, Jacobson MR, Cumberworth V et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 1992; 89:877-83.
6. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102:157-64.
7. Bousquet J, Lockey R, Malling HJ et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81:401-5.
8. Durham SR. The inflammatory nature of allergic disease. Clin Exp Allergy 1998; 28 (Suppl. 6):20-4.
9. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001; 107:87-93.
10. Durham SR, Ying S, Varney VA et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-65.
11. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102:98-106.
12. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-61.
13. Platts-Mills TA, Snajdr MJ, Ishizaka K, Frankland AW. Measurement of IgE antibody by an antigen-binding assay: correlation with PK activity and IgG and IgA antibodies to allergens. J Immunol 1978; 120:1201-10.
14. Varga EM, Wachholz P, Nouri-Aria KT et al. T cells from human allergen-induced late asthmatic responses express IL-12 receptor beta 2 subunit mRNA and respond to IL-12 in vitro. J Immunol 2000; 165:2877-85.
15. Brewer JM, Conacher M, Gaffney M, Douglas M, Bluethmann H, Alexander J. Neither interleukin-6 nor signalling via tumour necrosis factor receptor-1 contribute to the adjuvant activity of Alum and Freund's adjuvant. Immunology 1998; 93:41-8.
16. Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 1999; 163:6448-54.
17. Pollock KG, Conacher M, Wei XQ, Alexander J, Brewer JM. Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology 2003; 108:137-43.
18. Grun J, Maurer P. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cellular Immunol 1989; 121:134-45.
19. Cox JC, Coulter AR. Adjuvants - a classification and review of their modes of action. Vaccine 1997; 15:248-56.
20. Comoy EE, Capron A, Thyphronitis G. In vivo induction of type 1 and 2 immune responses against protein antigens. Int Immunol 1997; 9:523-31.
21. Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 2000; 12:456-63.
22. Brewer JM, Tetley L, Richmond J, Liew FY, Alexander J. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J Immunol 1998; 161:4000-7.
23. Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 2001; 69:1151-9.
24. Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996; 26:2062-6.
25. Sansom DM, Manzotti CN, Zheng Y. What's the difference between CD80 and CD86? Trends Immunol 2003; 24:313-8.
26. Collins AV, Brodie DW, Gilbert RJ et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17:201-10.
27. Telerman A, Amson RB, Romasco F, Wybran J, Galand P, Mosselmans R. Internalization of human T lymphocyte receptors. Eur J Immunol 1987; 17:991-7.
28. Durham SR, Varney V, Gaga M, Frew AJ, Jacobson M, Kay AB. Immunotherapy and allergic inflammation. Clin Exp Allergy 1991; 21 (Suppl. 1):206-10.
29. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
30. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997; 99:254-60.
31. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644-51.